<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(4)</volume><submitter>Murai N</submitter><pubmed_abstract>For a long time, ex vivo-expanded peripheral-blood-derived γδT cell (PBγδT)-based immunotherapy has been attractive, and clinical trials have been undertaken. However, the difficulty in expanding cytotoxic γδT cells to an adequate number has been a major limitation to the efficacy of treatment in most cases. We successfully re-generated γδT cells from γδT cell-derived human induced pluripotent stem cells (iPSCs). The iPSC-derived γδT cells (iγδTs) killed several cancer types in a major histocompatibility complex (MHC)-unrestricted manner. Single-cell RNA sequencing (scRNA-seq) revealed that the iγδTs were identical to a minor subset of PBγδTs. Compared with a major subset of PBγδTs, the iγδTs showed a distinctive gene expression pattern: lower CD2, CD5, and antigen-presenting genes; higher CD7, KIT, and natural killer (NK) cell markers. The iγδTs expressed granzyme B and perforin but not interferon gamma (IFNγ). Our data provide a new source for γδT cell-based immunotherapy without quantitative limitation.</pubmed_abstract><journal>Stem cell reports</journal><pagination>853-868</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10147660</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Re-generation of cytotoxic γδT cells with distinctive signatures from human γδT-derived iPSCs.</pubmed_title><pmcid>PMC10147660</pmcid><pubmed_authors>Terashi H</pubmed_authors><pubmed_authors>Koyanagi-Aoi M</pubmed_authors><pubmed_authors>Aoi T</pubmed_authors><pubmed_authors>Murai N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Re-generation of cytotoxic γδT cells with distinctive signatures from human γδT-derived iPSCs.</name><description>For a long time, ex vivo-expanded peripheral-blood-derived γδT cell (PBγδT)-based immunotherapy has been attractive, and clinical trials have been undertaken. However, the difficulty in expanding cytotoxic γδT cells to an adequate number has been a major limitation to the efficacy of treatment in most cases. We successfully re-generated γδT cells from γδT cell-derived human induced pluripotent stem cells (iPSCs). The iPSC-derived γδT cells (iγδTs) killed several cancer types in a major histocompatibility complex (MHC)-unrestricted manner. Single-cell RNA sequencing (scRNA-seq) revealed that the iγδTs were identical to a minor subset of PBγδTs. Compared with a major subset of PBγδTs, the iγδTs showed a distinctive gene expression pattern: lower CD2, CD5, and antigen-presenting genes; higher CD7, KIT, and natural killer (NK) cell markers. The iγδTs expressed granzyme B and perforin but not interferon gamma (IFNγ). Our data provide a new source for γδT cell-based immunotherapy without quantitative limitation.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2026-05-29T02:23:49.538Z</modification><creation>2025-02-19T02:24:24.848Z</creation></dates><accession>S-EPMC10147660</accession><cross_references><pubmed>36963392</pubmed><doi>10.1016/j.stemcr.2023.02.010</doi></cross_references></HashMap>